

A Retrospective Study to Characterize Participants With Propionic Acidemia

NCT05769621

| | |
|------------|-----------------|
| Status | RECRUITING |
| Sponsor | ModernaTX, Inc. |
| Enrollment | 60 participants |

Key Eligibility Criteria

Inclusion (13)

- Participants' medical records are eligible for abstraction only if all of the following criteria apply:
 - Confirmed diagnosis of PA based on diagnosis by molecular genetic testing (propionyl-CoA carboxylase subunit α [PCCA] and/or propionyl-CoA carboxylase subunit β [PCCB] mutations).
 - Participant provided informed consent (and assent, as applicable).
 - Medical records with sufficient data to support medical encounter for CEC adjudication (MEA adjudication) must be available dating back to birth or 01 January 2015, whichever occurs later. Participants born prior to 2015 will require additional information to confirm eligibility.
 - Experienced at least one MDE in the 24 months preceding the Index Date or experienced at least 3 MDEs within any one 12-month retrospective review period (based on Index Date) dating back to birth or 01 January 2015, whichever occurs later.
- ... and 8 more (see full listing online)

Exclusion (1)

- Participation (prior or ongoing) in clinical study mRNA-3927-P101 (NCT04159103) or mRNA-3927-P101-EXT (NCT05130437).

Locations (29 total)

University of Stanford Medical Center, Stanford, California, United States
Johns Hopkins University, Baltimore, Maryland, United States
University of Michigan Hospital, Ann Arbor, Michigan, United States
... and 26 more locations